Applied Therapeutics Reports Third Quarter 2019 Financial Results
“The third quarter was a critical period of progress at Applied, and we are extremely pleased to have met all of our objectives,” said
$20MPrivate Placement. In November 2019, we announced the close of a private placement of common stock, resulting in gross proceeds of approximately $20 million.
- Presented Data Highlighting AT-007 for the Treatment of Galactosemia at the ASHG Annual Meeting. In
October 2019, our Chief Medical Officer, Riccardo Perfetti, MD, PhD, gave an oral platform presentation highlighting AT-007 for the treatment of Galactosemia at the American Society of Human Genetics(ASHG) 2019 Annual Meeting in Houston. We also hosted an Educational Symposium featuring a panel of Galactosemia experts.
- Presented Preclinical and Clinical Data on AT-001 in Diabetic Cardiomyopathy (DbCM) at the EASD and HFSA Annual Meetings. In
September 2019, we presented preclinical and clinical proof of concept data on AT-001 in DbCM at the Heart Failure Society of America(HFSA) 23rd Annual Scientific Meeting in Philadelphia. In addition, we presented a preclinical poster on AT-001 at the 55th Annual Meeting of the European Association for the Study of Diabetes(EASD) in Barcelona, demonstrating that AT-001 significantly reduces cardiac damage in an animal model of DbCM. These data further support the development rationale and clinical proof of concept for AT-001 in DbCM.
- Initiated Phase 3 Registrational Trial of AT-001 in Diabetic Cardiomyopathy (ARISE-HF). In
September 2019, we announced the initiation of ARISE-HF, a Phase 3 registrational trial for AT-001 in Diabetic Cardiomyopathy (DbCM). ARISE-HF is a double-blind, placebo controlled, Phase 3 registrational trial expected to enroll approximately 675 type 2 diabetic patients with DbCM at high risk of progression to overt heart failure. ARISE-HF will assess AT-001’s ability to improve or prevent decline in exercise tolerance as measured by peak VO2 over 15 months of treatment. Additional supportive secondary and exploratory endpoints include percent of patients progressing to overt heart failure, quality of life metrics (modified KCCQ), echocardiographic measurements and cardiac stress biomarkers, including NTproBNP. At the conclusion of the core trial, patients may continue into a 12-month placebo-controlled extension study to assess potential impact on cardiovascular death and hospitalization.
- Reported Single and Multiple Ascending Dose Data from Healthy Volunteer Portion of Phase 1/2 ACTION-Galactosemia Trial Evaluating AT-007. In
August 2019, we announced the completion of the Single Ascending Dose healthy volunteer portion of the Phase 1/2 study of AT-007 in Galactosemia. In October, at the ASHG meeting, we provided an update on Multiple Ascending Dose portion of the study. AT-007 was well tolerated, with no drug-related adverse events or dose-limiting toxicities reported. The study, referred to as ACTION-Galactosemia, was initiated in June 2019and is designed to investigate the safety and pharmacokinetics (PK) of AT-007, a central nervous system (CNS) penetrant Aldose Reductase (AR) inhibitor in healthy volunteers, and biomarker effects in adult subjects with Galactosemia. Data from the adult Galactosemia patient portion of the trial is expected in the fourth quarter of 2019. We plan to employ recent FDAguidance permitting biomarker-based development in low prevalence, slowly progressing rare metabolic diseases, such as Galactosemia.
- Cash and cash equivalents and short-term investments totaled
$33.0 millionas of September 30, 2019, compared with $18.8 millionat December 31, 2018. Subsequent to the close of the quarter, we closed a private placement of common stock resulting in net proceeds of approximately $20 million.
- Research and development expenses for the three months ended
September 30, 2019were $7.5 million, compared to $2.7 millionfor the three months ended September 30, 2018. The increase of approximately $4.8 millionwas primarily related to the progressing of our clinical trials through development, including an increase in clinical and pre-clinical expenses of $4.0 millionand personnel expenses of $1.0 milliondue to the hiring of research and development personnel, including the Chief Medical Officer in August 2018. These increases are offset by a decrease in drug manufacturing and formulation expenses of $0.1 millionand decrease in regulatory and other expenses of $0.1 million.
- General and administrative expenses were
$3.3 millionfor the three months ended September 30, 2019, compared to $0.6 millionfor the three months ended September 30, 2018. The increase of approximately $2.7 millionwas primarily related to personnel expenses of $1.0 milliondue to the increase in headcount, including the hiring of the Chief Financial Officer, professional fees of $0.9 milliondue to increased legal and consulting fees, and other expenses of $0.8 million, primarily due to public relations efforts, travel expenses and recruiting efforts.
- Net loss for the third quarter of 2019 was
$10.7 million, or $0.63per basic and diluted common share, compared to a net loss of $4.3 million, or $0.78per basic and diluted common share, for the third quarter of 2018.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the design, scope and results of our clinical trials, (ii) the timing of the initiation and completion of our clinical trials, (iii) the likelihood that data from our clinical trials will support future development of our product candidates, (iv) the likelihood of obtaining regulatory approval of our product candidates and qualifying for any special designations, such as orphan drug designation, (v) our cash runway and the timing of our clinical development plan. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved. Such risks and uncertainties include, without limitation, the uncertainties inherent in the initiation, execution and completion of clinical trials, in the timing of availability of trial data, in the results of the clinical trials, in the actions of regulatory agencies, in the commercialization and acceptance of new therapies. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the
(212) 600-1902 or
Statement of Operations
|Three Months Ended||Nine Months Ended|
|September 30,||September 30,|
|Research and development||$||7,453||$||2,726||$||18,582||$||6,111|
|General and administrative||3,294||598||9,331||1,418|
|Total operating expenses||10,747||3,324||27,913||7,529|
|LOSS FROM OPERATIONS||(10,747||)||(3,324||)||(27,913||)||(7,529||)|
|OTHER INCOME (EXPENSE), NET:|
|Interest income (expense), net||34||(584||)||33||(1,400||)|
|Total other income (expense), net||34||(957||)||33||(2,273||)|
|Net loss attributable to common stockholders—basic and diluted||$||(10,713||)||$||(4,281||)||$||(27,880||)||$||(9,802||)|
|Net loss per share attributable to common stockholders—basic and diluted||$||(0.63||)||$||(0.78||)||$||(1.98||)||$||(1.79||)|
|Weighted-average common stock outstanding—basic and diluted||17,095,870||5,497,871||14,085,579||5,473,414|
|As of||As of|
|September 30,||December 31,|
|Cash and cash equivalents||$||13,065||$||18,748|
|Prepaid expenses and other current assets||4,080||1,498|
|Total current assets||37,034||20,246|
|LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)|
|Accrued expenses and other current liabilities||4,829||1,413|
|Total current liabilities||6,517||4,428|
|Series A convertible preferred stock, $0.0001 par value; 0 shares and 3,093,898 shares authorized at September 30, 2019 and December 31, 2018, respectively; 0 shares and 3,093,898 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively; liquidation preference of $0 and $7,000 at September 30, 2019 and December 31, 2018, respectively||—||6,254|
|Series B convertible preferred stock, $0.0001 par value; 0 shares and 7,790,052 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 0 shares and 4,001,848 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively; liquidation preference of $0 and $29,964 as of September 30, 2019 and December 31, 2018, respectively||—||29,156|
|STOCKHOLDERS’ EQUITY (DEFICIT):|
|Common stock, $0.0001 par value; 100,000,000 and 20,441,982 shares authorized as of September 30, 2019 and December 31, 2018, respectively; 17,134,190 shares and 5,513,531 shares issued and outstanding as of September 30, 2019 and December 31, 2018, respectively||1||—|
|Additional paid-in capital||79,872||1,665|
|Accumulated other comprehensive loss||11||—|
|Total stockholders' equity (deficit)||30,747||(19,592||)|
|TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)||$||37,264||$||20,246|
Source: Applied Therapeutics